Prospective clinical trial of Intravitreal aflibercept treatment for Polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results

Gregg T. Kokame1,2,3,4*, James C. Lai1,2,3,4, Raymond Wee2,3,4, Ryan Yanagihara2,3,4,5, Jessica G. Shantha2,3,4, Julia Ayabe5 and Kelsi Hirai5

Abstract

Background: Polypoidal choroidal vasculopathy is a variant of choroidal neovascularization and neovascular age related macular degeneration presenting with hemorrhagic and exudative changes within the macula and/or peripapillary region leading to vision loss. In contrast to neovascular age related macular degeneration, polypoidal choroidal vasculopathy has differing clinical manifestations and treatment strategies. Historically, polypoidal choroidal vasculopathy complexes are less responsive to anti-vascular endothelial growth factor therapy with no prospective clinical trials evaluating aflibercept in management of polypoidal choroidal vasculopathy. Herein we prospectively evaluate the efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy.

Methods: A prospective, open-label, investigator-sponsored trial of intravitreal aflibercept for polypoidal choroidal vasculopathy in 21 eyes was conducted. Injections were administered monthly for 3 initial treatments, then every other month with monthly evaluations. The primary outcome measures were the mean change in best corrected visual acuity and adverse events. Secondary outcome measures included stabilization of vision, presence of subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment, and regression of polypoidal complexes on indocyanine green angiography.

Results: At 6 months, the median visual acuity was 20/40 (range 20/25–20/200) with a mean Early Treatment Diabetic Retinopathy Study vision of 68.4 letters. There was a gain of 2.76 Early Treatment Diabetic Retinopathy Study letters at 6 months (p = 0.15). No patient developed severe vision loss (≤15 letters) and vision was stable or improved in 19/21 eyes (91%). Subretinal fluid resolved in 13/18 eyes (72%), and subretinal hemorrhage resolved in 6/8 eyes (75%) respectively. The polyps regressed in 14/21 eyes (67%) and the branching vascular network decreased in 1 eye and was stable in all other eyes. The retinal pigment epithelial detachment improved in 13/15 eyes (87%). Bimonthly treatment occurred in 15/21 patients (71%). There were no adverse events.

(Continued on next page)
Conclusions: Intravitreal aflibercept results in stabilization of vision, resolution of exudative and hemorrhagic complications with regression of polyps in polypoidal choroidal vasculopathy. Eyes with polypoidal choroidal vasculopathy previously treated with ranibizumab and bevacizumab can show marked improvement in the retinal pigment epithelial detachments and persistent polyps with aflibercept therapy.

Trial registration: Clinical trials.gov NCT01871376, June 4th 2013

Keywords: Choroidal neovascularization, Polypoidal choroidal vasculopathy, Aflibercept, Exudative macular degeneration, Retinal pigment epithelial detachment

Background
Polypoidal choroidal vasculopathy (PCV) is increasingly recognized as a cause of exudative and hemorrhagic complications in the macula [1–3]. Patients with PCV present with subretinal hemorrhage, subretinal fluid, and retinal pigment epithelial detachment (RPED). These findings are associated with a subretinal branching vascular network (BVN) with characteristic “polyplike” structures at the terminal ends of the vessels [1–5]. Since many of the fundus and optical coherence tomography (OCT) findings are similar to typical exudative age related macular degeneration (AMD), indocyanine green (ICG) angiography is essential to diagnosing PCV [1, 5]. Polypoidal choroidal vasculopathy is a variant of type I subretinal neovascularization (Gass classification) [6], in which the neovascular complex grows beneath the retinal pigment epithelium (RPE) and above Bruch’s membrane [7–9].

The treatment of the hemorrhagic and exudative complications of PCV is not well defined, but therapeutic approaches include photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) therapy, combined PDT and anti-VEGF therapy, direct thermal laser to polyps, and surgical management of significant subretinal hemorrhage or hemorrhagic retinal detachment [10]. Photodynamic therapy has been the mainstay of treatment in Asia for years [11–14], and was supported by an expert panel on PDT management in Asia. This treatment is usually guided by the size of the complex on ICG angiography. [11]. Polypoidal choroidal vasculopathy is much more common in Asian populations and is being increasingly recognized in White populations with more frequent use of ICG angiography [3, 15–20].

Anti-VEGF therapy has recently been shown to be effective in decreasing the exudation, macular edema, and hemorrhage associated with PCV [12, 21–25]. Although retrospective studies are numerous, there are very limited prospective studies available for evaluation of the different anti-VEGF agents. For ranibizumab treatment in PCV, there are 6 month prospective results available in the Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy trial (EVEREST trial ranibizumab 0.5 mg) [12], in the investigator sponsored trial for Polypoidal Choroidal Vasculopathy with Intravitreal Ranibizumab (PEARL trial, ranibizumab 0.5 mg) [21, 23], and in the investigator sponsored trial of Polypoidal Choroidal Vasculopathy Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2 trial, 2.0 mg ranibizumab) [8]. For aflibercept, only one recent prospective study of aflibercept 2.0 mg exists in treatment naïve eyes with exudative or hemorrhagic PCV [22]. The Prospective Clinical Trial of Intravitreal Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Hemorrhage or Exudation trial (EPIC trial) results reported herein provides 6 month results on eyes with PCV that were both treatment naïve, as well as eyes previously treated with anti-angiogenic therapy, including treatment with high dose ranibizumab therapy (ranibizumab 1.0 mg or 2.0 mg) for 24 months in the PEARL2 trial.

Methods
The EPIC trial (Intravitreal Aflibercept Injections (Eylea®) for Polypoidal Choroidal Vasculopathy with Hemorrhage or Exudation) is an ongoing, prospective, open-label clinical trial of intravitreal aflibercept (2.0 mg/0.05 mL) in patients with active hemorrhage, exudation, or recent decrease in vision (defined as a loss of five Early Treatment Diabetic Retinopathy Study letters (ETDRS) or one Snellen line of vision in the past 6 months) associated with PCV. Major exclusion criteria include: (1) history of previous vitrectomy; (2) previous cataract surgery within 2 months prior to the baseline visit; (3) presence of any condition that would jeopardize the patient’s participation in this study; (4) no prior anti-VEGF (pegaptanib, bevacizumab, ranibizumab, aflibercept) in study eye within 30 days of enrollment; (5) known allergy to the study drug; (6) poorly controlled hypertension; (7) major surgery within 28 days prior to study. The EPIC study was approved by the Western Institutional Review Board (IRB, Puyallup, Washington, Study Number 1138211) and listed on clinical trials.gov (NCT01871376). The study was carried out at The
Retina Center at Pali Momi. It adhered to the tenets of the guidelines of the Declaration of Helsinki, and each patient completed a written informed consent. The EPIC trial also followed the TREND guidelines/methodology. This study was supported in part as an investigator-sponsored trial by a research grant from Regeneron, Inc (Tarrytown, New York). The investigators maintained complete control of the data and its interpretation.

The clinical diagnosis of PCV was based on funduscopic identification of serous retinal detachment, macular edema, subretinal hemorrhage, or RPED. The definitive diagnosis was confirmed by ICG angiography, in which PCV complexes were identified as polyps with or without a BVN (Fig. 1). All patients received multiple, open-label intravitreal injections of 2.0 mg aflibercept (Regeneron, Tarrytown, New York, United States) administered per protocol for 6 months. The first 3 months required monthly mandatory dosing (30 days ± 7 days) (baseline, month 1, month 2). Subsequent injections were administered every other month (60 days ± 7 days). If needed, patients were allowed monthly treatment (30 days ± 7 days), if there was recurrence or persistence of subretinal fluid, subretinal hemorrhage or macular edema with or without vision loss. Recurrence of subretinal fluid or hemorrhage after previous resolution of subretinal fluid or hemorrhage required three consecutive monthly mandatory injections before a possible monthly examination without treatment could be considered.

At baseline all patients had a complete ophthalmic examination with best corrected visual acuity determined with ETDRS charts and refraction at 4 m (BCVA), slit-lamp examination, funduscopic biomicroscopic examination, fundus photography, fundus autofluorescence testing, fluorescein angiography (FA), and ICG angiography using the scanning laser ophthalmoscope (Heidelberg Spectralis HRA + OCT, Heidelberg Engineering USA, Carlsbad, California) and optical coherence tomography (OCT) with point-to-point localization of the OCT with the FA and ICG angiography landmarks. Ophthalmic examination, visual acuity, fundus autofluorescence (FAF), and OCT were performed monthly. Early Treatment Diabetic Retinopathy

![Fig. 1 Marked reduction of treatment-naive polyp after 6 months of intravitreal aflibercept.](image)

- a. EPIC study baseline ICG angiogram (left) with correlated OCT study (right). Note the hyperfluorescent polyp with hypofluorescent ring on ICG angiogram. On the OCT, an inverted U-shaped polyp (arrow) is seen with surrounding serous detachment.
- b. ICG angiogram (left) following 6 months of intravitreal aflibercept with corresponding OCT (right) reveals marked reduction in the polyp (arrow)
Study vision at 4 m, FA, and ICG angiography were performed at baseline, and at 1, 3, and 6 months. Eyes will be followed in the study for 24 months.

The primary outcome measures are the mean change in BCVA and the incidence and severity of ocular and systemic adverse events. Secondary outcome measures included stabilization of vision (loss of ≥15 ETDRS letters), changes in subretinal fluid, presence of subretinal hemorrhage, decrease in R PED, change in central foveal thickness (CFT), presence of macular edema, leakage on fluorescein angiography, and regression of polypoidal complexes on ICG angiography. The PCV complex was composed of polyp lesions and a BVN in all patients. Both components were evaluated separately. Decrease in polyp lesion or BVN was any decrease in size or number of polyps as compared to baseline imaging. Stable findings of the polyp or BVN indicates no change in size or number of polyps in response to therapy. Regression and/or resolution of the polyp indicates that it has resolved on ICG. Macular edema was defined as an increase in macular thickness including subretinal fluid and intraretinal edema as visualized on OCT. Paired t-tests were performed to compare baseline and 6 month ETDRS best corrected visual acuity and change in OCT CFT. Statistical significance was based on p values <0.05 and the statistical analysis was performed using SAS 9.2 software (Cary, North Carolina).

Results
Baseline characteristics of patients entered into the EPIC trial can be found in Table 1. Patients were treated with bevacizumab and/or ranibizumab with a range of 1 to 36 injections in the 11 patients previously treated with anti-VEGF therapy. Before entering the EPIC trial, patients did not receive an injection within 30 days of screening and had active disease at entry. The one patient with prior PDT had two PDT treatments over 2 years before entering the EPIC trial and had developed recurrent leakage and serous detachment upon entry. All patients with active leakage or bleeding associated with PCV were offered entry into the EPIC trial. Baseline findings included subretinal fluid in 18/21 eyes (86), subretinal/sub-RPE hemorrhage in 8/21 eyes (38), and R PED in 15/21 eyes (71 %). On ICG angiography polypoidal complexes were in the macula in 17 eyes (81), in the peripapillary region alone in 1 eye (5), and in both the macular and peripapillary regions in 3 eyes (14 %) at the baseline EPIC study visit. The median BCVA was 20/40 (range: 20/16 – 20/200) at baseline and 20/40 (range: 20/25 – 20/200) at 6 months. The BCVA was 20/32 or better at baseline in 11/21 eyes (52 %). The range of vision in the remaining 10 eyes was from 20/40 to 20/200. The mean ETDRS BCVA was 65.7 letters at baseline, and 68.4 letters at 6 months (Table 2). The average gain in ETDRS letters over 6 months was 2.76 letters (p = 0.15). None of the patients lost ≥15 letters in ETDRS vision at 6 months. One patient (5 %) gained ≥15 letters at 6 months (Fig. 2). Six eyes (29) improved ≥5 letters, thirteen eyes (61) remained unchanged (<5 letter change) from baseline, and two eyes (10 %) decreased ≥5 letters. The changes in ETDRS letters based on previous treatment can be found in Table 3.

At 6 months, subretinal hemorrhage resolved in 6/8 eyes (75), persisted in 1/8 eyes (12.5), and increased in 1/8 eyes (12.5 %). Subretinal fluid completely resolved in 13/18 eyes (72 %), decreased in 3/18 eyes (17 %), and remained stable in 2/18 eyes (11 %). A statistical significant decrease was noted in the comparison of the average CFT at baseline (282 μm) and at 6 months (207 μm) with an average decrease of 75 μm (p = 0.0014, Table 2). The R PED resolved completely or decreased in 13/15 eyes (87 %) (Fig. 3), stable in 1/15 eyes (7 %), and increased in 1/15 eyes (7 %). Significant macular edema at baseline due to PCV was present in 17/21 eyes (81 %). In these 17 eyes, macular edema improved in 13/17 eyes (76 %). In 4 cases, the edema remained stable.

At 6 months 15/21 eyes (71 %) received treatment every other month per EPIC protocol. The remaining 6 eyes (29 %) were receiving monthly injections at month 6. This included 3 eyes with 6 monthly injections, and 3 eyes with 5 injections. Two patients had recurrences both occurring at month 4. These recurrences then necessitated restarting monthly therapy for 3 aflibercept treatments. One patient missed a follow-up evaluation at

| Table 1 Baseline Characteristics of the EPIC Study |
|-----------------------------------------------|
| Characteristic                                |
| Mean Age, Years (Range)                       |
| Males, N (%)                                  |
| Ethnicity, N (%)                              |
| Asian                                         |
| Caucasian                                     |
| Laterality, N (%)                             |
| Unilateral                                    |
| Bilateral                                     |
| Prior Treatment, N (%)                        |
| Prior Anti-VEGF                               |
| Prior ML                                      |
| Prior PDT                                     |
| None (Treatment-Naïve)                        |
| Median Visual Acuity (Range)                  |
| Mean ETDRS Letters (Range)                    |
| Mean Central Foveal Thickness, (μM)           |
| VEGF vascular endothelial growth factor, ML macular laser, PDT Photodynamic therapy, ETDRS Early Treatment Diabetic Retinopathy Study, μm micrometers, n number |

| Study vision at 4 m, FA, and ICGangiography were performed at baseline, and at 1, 3, and 6 months. Eyes will be followed in the study for 24 months. |
| The primary outcome measures are the mean change in BCVA and the incidence and severity of ocular and systemic adverse events. Secondary outcome measures included stabilization of vision (loss of <15 ETDRS letters), changes in subretinal fluid, presence of subretinal hemorrhage, decrease in R PED, change in central foveal thickness (CFT), presence of macular edema, leakage on fluorescein angiography, and regression of polypoidal complexes on ICG angiography. The PCV complex was composed of polyp lesions and a BVN in all patients. Both components were evaluated separately. Decrease in polyp lesion or BVN was any decrease in size or number of polyps as compared to baseline imaging. Stable findings of the polyp or BVN indicates no change in size or number of polyps in response to therapy. Regression and/or resolution of the polyp indicates that it has resolved on ICG. Macular edema was defined as an increase in macular thickness including subretinal fluid and intraretinal edema as visualized on OCT. Paired t-tests were performed to compare baseline and 6 month ETDRS best corrected visual acuity and change in OCT CFT. Statistical significance was based on p values <0.05 and the statistical analysis was performed using SAS 9.2 software (Cary, North Carolina). |
| Results |
| Baseline characteristics of patients entered into the EPIC trial can be found in Table 1. Patients were treated with bevacizumab and/or ranibizumab with a range of 1 to 36 injections in the 11 patients previously treated with anti-VEGF therapy. Before entering the EPIC trial, patients did not receive an injection within 30 days of screening and had active disease at entry. The one patient with prior PDT had two PDT treatments over 2 years before entering the EPIC trial and had developed recurrent leakage and serous detachment upon entry. All patients with active leakage or bleeding associated with PCV were offered entry into the EPIC trial. Baseline findings included subretinal fluid in 18/21 eyes (86), subretinal/sub-RPE hemorrhage in 8/21 eyes (38), and R PED in 15/21 eyes (71 %). On ICG angiography polypoidal complexes were in the macula in 17 eyes (81), in the peripapillary region alone in 1 eye (5), and in both the macular and peripapillary regions in 3 eyes (14 %) at the baseline EPIC study visit. The median BCVA was 20/40 (range: 20/16 – 20/200) at baseline and 20/40 (range: 20/25 – 20/200) at 6 months. The BCVA was 20/32 or better at baseline in 11/21 eyes (52 %). The range of vision in the remaining 10 eyes was from 20/40 to 20/200. The mean ETDRS BCVA was 65.7 letters at baseline, and 68.4 letters at 6 months (Table 2). The average gain in ETDRS letters over 6 months was 2.76 letters (p = 0.15). None of the patients lost ≥15 letters in ETDRS vision at 6 months. One patient (5 %) gained ≥15 letters at 6 months (Fig. 2). Six eyes (29) improved ≥5 letters, thirteen eyes (61) remained unchanged (<5 letter change) from baseline, and two eyes (10 %) decreased ≥5 letters. The changes in ETDRS letters based on previous treatment can be found in Table 3. At 6 months, subretinal hemorrhage resolved in 6/8 eyes (75), persisted in 1/8 eyes (12.5), and increased in 1/8 eyes (12.5 %). Subretinal fluid completely resolved in 13/18 eyes (72 %), decreased in 3/18 eyes (17 %), and remained stable in 2/18 eyes (11 %). A statistical significant decrease was noted in the comparison of the average CFT at baseline (282 μm) and at 6 months (207 μm) with an average decrease of 75 μm (p = 0.0014, Table 2). The R PED resolved completely or decreased in 13/15 eyes (87 %) (Fig. 3), stable in 1/15 eyes (7 %), and increased in 1/15 eyes (7 %). Significant macular edema at baseline due to PCV was present in 17/21 eyes (81 %). In these 17 eyes, macular edema improved in 13/17 eyes (76 %). In 4 cases, the edema remained stable. At 6 months 15/21 eyes (71 %) received treatment every other month per EPIC protocol. The remaining 6 eyes (29 %) were receiving monthly injections at month 6. This included 3 eyes with 6 monthly injections, and 3 eyes with 5 injections. Two patients had recurrences both occurring at month 4. These recurrences then necessitated restarting monthly therapy for 3 aflibercept treatments. One patient missed a follow-up evaluation at |
Table 2 Comparisons of change in clinical manifestations at baseline and 6 months

| Patients | ETDRS letters baseline | ETDRS letters 6 months | CFT baseline (μM) | CFT 6 months (μM) | Polyps At 6 months (ICG) | BVN At 6 months (ICG) |
|----------|------------------------|------------------------|-------------------|-------------------|-------------------------|-----------------------|
| 1        | 71                     | 70                     | 210               | 199               | =                       | =                     |
| 2        | 30                     | 60                     | 176               | 119               | ↓                       | =                     |
| 3        | 72                     | 68                     | 230               | 235               | R                       | =                     |
| 4        | 75                     | 73                     | 398               | 177               |                         | =                     |
| 5        | 48                     | 49                     | 276               | 218               | ↓                       | =                     |
| 6        | 75                     | 68                     | 318               | 188               |                         | =                     |
| 7        | 58                     | 72                     | 278               | 289               |                         | =                     |
| 8        | 59                     | 68                     | 352               | 343               |                         | =                     |
| 9        | 74                     | 83                     | 237               | 227               | R                       | =                     |
| 10       | 82                     | 80                     | 550               | 198               | ↓                       | ↓                     |
| 11       | 80                     | 81                     | 249               | 183               | R                       | =                     |
| 12       | 38                     | 37                     | 208               | 193               | ↓                       | =                     |
| 13       | 60                     | 67                     | 317               | 227               | R                       | =                     |
| 14       | 36                     | 38                     | 387               | 163               | ↓                       | =                     |
| 15       | 83                     | 80                     | 223               | 200               | =                       | =                     |
| 16       | 73                     | 77                     | 222               | 221               | ↑                       | =                     |
| 17       | 74                     | 76                     | 346               | 220               | R                       | =                     |
| 18       | 89                     | 83                     | 196               | 178               | ↓                       | =                     |
| 19       | 74                     | 73                     | 290               | 223               | ↓                       | =                     |
| 20       | 61                     | 70                     | 315               | 190               | ↓                       | =                     |
| 21       | 67                     | 64                     | 164               | 158               | R                       | =                     |

CFT: Central foveal thickness, ETDRS: Early Treatment Diabetic Retinopathy Study, BVN: Branching vascular network, ICG: Indocyanine green angiography, ↑ = increased, ↓ = decreased, = =stable, R regressed

month 3. This patient had persistent subretinal fluid throughout the study and required monthly treatment.

The response of the polypoidal complex to aflibercept therapy utilizing the EPIC protocol was evaluated with ICG angiography (Table 2). Polyps resolved or decreased in 14/21 eyes (67 %) (Figs. 1, 4). Complete polyp regression was noted in 6/21 eyes (29 %). Polyps remained stable in 6/21 (29 %) eyes. In one eye (5 %), there was a localized increase in the inferior peripheral polyps along the PCV complex on aflibercept therapy, the BVN remained stable in size without associated bleeding or leaking at 6 months. The BVN remained the same size in 20 eyes (95) and decreased in one eye (5 %). In the 15 eyes presenting with RPED, the polypoidal complex may then show increased visibility of the BVN (Fig. 3c). This was noted in 9 of the 15 eyes (60 %) initially presenting with RPED, where 13 eyes showed significant flattening of the RPED (Fig. 3 a, b). In one eye that had received 24 months of high dose ranibizumab in the PEARL2 study, there was a marked reduction in polyps on aflibercept at 6 months (Fig. 4).

On fundus autofluorescence at baseline polyps were seen as hyperautofluorescent with a surrounding hypoautofluorescent ring in 9 eyes, hyperautofluorescent in 3 eyes, hypoautofluorescent in 6 eyes, and hypoautofluorescent with hyperautofluorescent ring in 2 eyes. The BVN was visualized as hypoautofluorescent in 13 eyes, hyperautofluorescent in 6 eyes and not visualized 2 eyes respectively. At 6 months polyps were not visualized in 10 eyes, hyperautofluorescent in 4 eyes, hypoautofluorescent in 5 eyes, hypoautofluorescent with hyperautofluorescent ring in 2 eyes. The BVN’s at 6 months were hypoautofluorescent in 14 eyes, hyperautofluorescent in 3 eyes, and not visualized in 4 eyes. The BVN’s in these patients had indistinct borders. At baseline 4 patients had blocked autofluorescence due to SRH which resolved in 3 patients at 6 months. In 4 patients there were areas of diffuse hyper-autofluorescence within the macula.

There were no ocular or systemic adverse events noted in the study at 6 months.

Discussion

Polypoidal choroidal vasculopathy is a major cause of leaking and bleeding in the macula and may respond differently to therapeutic agents than typical exudative AMD [8, 9]. In the EPIC study, aflibercept was evaluated in an IRB-approved, prospective, clinical trial as an intravitreal therapy for PCV in eyes with confirmation of the PCV diagnosis by ICG angiography. Significant resolution of leaking and bleeding was noted in response to aflibercept. A statistical significant decrease in CFT was observed in these subset of patients. In addition, significant reduction was noted in RPED in 87 % of cases (Fig. 3). In the PEARL study (ranibizumab 0.5 mg) there was a 50 % reduction in RPED [21], and in the PEARL2 study (2.0 mg ranibizumab) there was a 63 % reduction in RPED [8]. In one patient entering the EPIC study there was a persistent large RPED after 24 monthly high dose ranibizumab injections in the PEARL2 study. After entering the EPIC trial with aflibercept, the highly elevated vascularized RPED resolved at 3 months and remained flat at month 6 with maintenance of stable vision (Fig. 3a). A greater resolution of RPED has also been noted after switching from bevacizumab and ranibizumab to aflibercept in multiple studies on therapy for wet AMD [26, 27]. ICG angiography was not performed in these studies, but vascularized RPED is more frequent.
in eyes with PCV than in eyes with typical exudative AMD.

Previous studies have demonstrated a higher rate of polyp regression in therapies utilizing PDT, or combination PDT and intravitreal injection of antiangiogenic drug. In the EVEREST study at 6 months there was a 77.8 % polyp closure rate with PDT + ranibizumab, a 71.4 % polyp closure rate with PDT alone, and a 28.6 % polyp closure rate with ranibizumab monotherapy [12]. However, there was not a statistically significant difference in vision results. The PEARL trial confirmed a relatively low rate of polyp regression of 33 % at 6 months [21], and 38 % after one year of monthly 0.5 mg ranibizumab therapy [23]. The PEARL, PEARL2 and EPIC studies are different prospective trials with different agents and different patient populations with relatively small sample sizes, so comparison between studies cannot be directly made. However, the ETDRS vision testing, OCT evaluation, and ICG angiography evaluations were consistent across all 3 studies. The anatomic data does show a higher polyp regression rate in the EPIC study of 67 %. In the PEARL study, the polyp regression rate was 33 % at 6 months [21] and in the PEARL2 study the polyp regression rate was 63 % at 6 months [8], but this dose is not commercially available. In one patient previously treated with high dose ranibizumab in the PEARL2 study, there were marked persistent polyps, which markedly regressed after 6 months of treatment with aflibercept in this EPIC study (Fig. 4).

Because half of the eyes entering into the EPIC study had a BCVA of 20/32 or better, a significant improvement in vision (>15 letters) could not be demonstrated in these eyes due to the ceiling effect. There was not a statistically significant improvement in mean BCVA in this patient population with good baseline vision, but the primary endpoint for vision showed that none of the

Table 3 Comparison of change in ETDRS from baseline 6 months of treatment in the EPIC trial

| Change in ETDRS letters | Treatment naïve (%) | Previously treated (%) | Total |
|-------------------------|---------------------|------------------------|-------|
| Improved ≥ 5 Letters    | 3 (30)              | 3 (27)                 | 6     |
| Unchanged < 5 Letters   | 6 (60)              | 7 (64)                 | 13    |
| Decreased ≥ 5 Letters   | 1 (10)              | 1 (9)                  | 2     |
| Increase ≥ 15 Letters   | 0                   | 0                      | 0     |
| Decrease ≥ 15 Letters   | 0                   | 1 (9)                  | 1     |

ETDRS Early Treatment Diabetic Retinopathy Study

Fig. 2 ICG angiogram with correlated OCT study in a previously treated eye in the PEARL 2 Study (12 2.0 mg ranibizumab + 12 1.0 mg ranibizumab) with additional bevacizumab intravitreal injections prior to entry into the EPIC study. a. Baseline EPIC Study images. ICG angiogram shows hypofluorescence (see arrowhead) in the area of the subretinal hyperreflective material and the central RPED. OCT shows a central RPED (arrow) with nasal subretinal hyperreflective material (asterisk). b. EPIC Month 6 imaging. ICG angiogram shows decrease in the area of hypofluorescence. OCT shows resolution of the subretinal hyperreflective material and decrease in the RPED. Visual acuity improved from 20/160 to 20/63 (+30 letters)
patients developed severe vision loss (>15 letters). The great majority of eyes showed stability of vision with 90% showing no loss of vision of greater than 5 ETDRS letters after 6 months.

PCV tends to have a higher incidence of anti-VEGF resistance [19], but in the EPIC study 71% of eyes were able to be treated with every other month therapy at month 6 after the initial 3 monthly aflibercept treatments. Only one of these eyes developed recurrence at month 6, and then required monthly therapy. In one case treated in the PEARL2 study after 24 months of monthly high dose ranibizumab therapy there was marked resolution of persistent polyps on therapy with aflibercept (Fig. 4). This high rate of polyp closure with aflibercept was confirmed in the recent study by Hosokawa and colleagues with a 77.7% resolution rate of polyps [22]. In another patient that was previously treated with ranibizumab in the PEARL2 Study and

**Fig. 3** Resolution of a vascularized RPED after aflibercept therapy. 

- **a.** An Asian male with a persistent large vascularized RPED after 24 months of high dose ranibizumab therapy (12 2.0 mg ranibizumab + 12 1.0 mg ranibizumab injections) in PEARL2 study at EPIC baseline (upper left). Resolution of the vascularized RPED which initially resolved at month 3 and stayed resolved at month 6 (upper right) 
- **b.** Treatment naïve Caucasian female with vascularized RPED at EPIC baseline (left) and after aflibercept therapy at month 6 (right). Note the marked improvement in the vascularized RPED. 
- **c.** Corresponding ICG angiogram to patient in B. Increased visibility of BVN after RPED resolution on aflibercept therapy. ICG angiogram shows hypofluorescence in the area of the RPED at baseline with inferior PCV complex (left). Follow-up ICG angiogram shows decreased hypofluorescence due to resolution of the RPED. Note the increased visibility of the hyperfluorescent BVN (right)
intravitreal bevacizumab, a persistent RPED with hyperreflective material was noted prior to entry into the EPIC trial. After treatment with aflibercept the central RPED decreased with resolution of the subretinal hyperreflective material and BCVA improvement from 20/160 to 20/63. This patient had a better anatomical and visual acuity response to aflibercept therapy than the previous anti-VEGF therapies highlighting the use of aflibercept in PCV patients that may not respond completely to other agents (Fig. 2).

Fundus autofluorescence was performed in all patients. At baseline there was more abnormalities as previously described by Koizumi as hyperautofluorescent lesions with a hypoautofluorescent ring, but this was less noticeable after treatment. This technique of imaging produced varied results of the characteristic polyps and BVN’s when compared to ICG. The BVN in all patients had indistinct borders making it difficult to distinguish lesion extent. In select patients areas of diffuse hyperautofluorescence were noted corresponding to areas of previous leakage with RPE stress [28].

While this study was designed as a prospective, open-label, clinical trial there are still limitations present. One is the small sample size, in which larger prospective clinical trials with treatment of PCV are necessary to further define and validate the appropriate treatment algorithms. This study included patients that have been previously treated with PDT and/or anti-VEGF therapy which might negate responses to the current therapy. Lastly, the initial visual acuity criteria being very good at entry
led to the inability to detect a statistical significant change in vision after treatment due to the ceiling effect.

The EPIC results are promising for the treatment of PCV in resolution of the leaking and bleeding complications of PCV, as well as in regards to increased resolution of the PCV complex. In addition, duration of therapy may allow less frequent dosing, as 71 % of cases were treated with every other month therapy by month 6. Possible etiologies for this increased effect in PCV are the higher binding affinity of aflibercept, as well as possible active transport of the aflibercept molecule across the RPE cells. As shown in pre-clinical studies, ranibizumab depends on a gradient diffusion between RPE cells, whereas aflibercept is actively transported to the subretinal pigment epithelial space by RPE cells [29].

Conclusion
Intravitreal aflibercept therapy is an effective treatment in PCV. It can stabilize vision, resolve exudative and hemorrhagic complications in the macula, and promote polyp regression within the PCV complex. Future studies with longer term results and larger numbers of patients will help to further guide aflibercept’s role in PCV management.

Additional file
Additional file 1: Epic 6 Month Results. The data in this supplementary table consists of both descriptive anatomical descriptions and quantitative data that was used to determine the effect aflibercept therapy had on the hemorrhagic and exudative changes within the macula. (XLS 107 kb)

Abbreviations
AMD, age related macular degeneration; BVN, branching vascular network; CFT, central foveal thickness; EPIC, prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation; ETDRS, Early Treatment Diabetic Retinopathy Study; EVEREST, efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy; FA, fluorescein angiography; ICG, indocyanine green angiography; IRB, Institutional Review Board; OCT, optical coherence tomography; PCV, polypoidal choroidal vasculopathy; NVAMD, neovascular age related macular degeneration; PDT, photodynamic therapy; PEARL 2, investigator sponsored trial of Polypoidal Choroidal Vasculopathy Evaluation Assessing High-Dose Ranibizumab Prospectively; RPED, retinal pigment epithelial detachment; VEGF, vascular endothelial growth factor

Acknowledgments
Shelia Chamian, Research Coordinator, Retina Consultants of Hawaii, Alison Zenel, Research Coordinator, Retina Consultants of Hawaii, Namrata Saroj, O.D, Senior Medical Director, Ophthalmic Medical Affairs, Regeneron Pharmaceuticals, Inc. Collaborator: John A. Burns School of Medicine

Funding
This work was supported as an investigator-sponsored trial by Regeneron Pharmaceuticals (Tarrytown, New York). Regeneron participated in study design and funding of this study.

Availability of data and materials
The data supporting this research will be uploaded as Additional file 1. The patient numbers used in the supplementary table and in the manuscript are different from actual study numbers used in the EPIC trial and identifying characteristics have been removed.

Authors’ contributions
Conception and design of work: GK, JL, RW. The acquisition of data: RY, JA, KH. The analysis of data: GK, RY, JS. Drafting the work and final approval of the work published: GK, RY, JL, RW, JS, JA, JH. All authors have read and approved the final manuscript. Dr. GK: Dr. JL, Dr. RW, Dr. RS, Dr. JS, JA, KH.

Competing interests
This study was supported by a research grant from Regeneron Pharmaceuticals (Tarrytown, New York) as an investigator-sponsored trial. The authors maintained control of the data and its interpretation. The authors do not have any personal financial interest in any related stocks, or proprietary interest in any related companies. Other Research Support: Genentech (multi-centered trial), Alcon (multi-centered trial), Allergan (multi-centered trial), Santen (multi-centered trial), Consultant – Santen GK, Regeneron GK, Bayer GK, Zeiss GK, Bausch and Lomb GK, Allergan GK, JL, Speaker – Regeneron GK, Bayer GK.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was ethically approved by the Western Institutional Review Board (Puyallup, Washington) (Study Number 11382211) and listed on clinical trials.gov (NCT01871376, June 4th 2013). It adhered to the tenets of the guidelines of the Declaration of Helsinki, and each patient completed a written informed consent to participate in this study.

Author details
1Division of Ophthalmology, Department of Surgery, University of Hawaii School of Medicine, 651 Ilalo St, Honolulu, HI 96813, USA. 2The Retina Center at Pali Momi, 98-1079 Moanalua Road, Suite 470, Aiea, Hawaii 96701, USA. 3Retina Consultants of Hawaii, 1380 Lusitana St #506, Honolulu, HI 96813, USA. 4Hawaii Macula and Retina Institute, 98-1079 Moanalua Road, Suite 470, Aiea, Hawaii 96701, USA. 5John A. Burns School of Medicine, University of Hawaii School of Medicine, 651 Ilalo St, Honolulu, HI 96813, USA.

Received: 23 February 2016 Accepted: 18 July 2016

Published online: 27 July 2016

References
1. Kokame GT. Polypoidal choroidal vasculopathy – an important diagnosis to make with therapeutic implications. Retina. 2012;32(8):1446–8.
2. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115(4):478–85.
3. Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol. 2008;19:208–12.
4. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy. Retina. 1999;19(1):1–8.
5. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green video angiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15(2):100–10.
6. Cass JD. Stereoscopic atlas of macular diseases. 4th ed. St Louis, Missouri: C.V. Mosby; 1997. p. 26–30.
7. Khan S, Engelbert M, Imamura Y, et al. Polypoidal choroidal vasculopathy. Simultaneous indocyanine green angiography and Eye-tracked spectral domain optical coherence tomography findings. Retina. 2012;32(6):1057–68.
8. Kokame GT. Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2014;112:74–93.
9. Kokame GT. Polypoidal choroidal vasculopathy – a type I polypoidal subretinal neovasculopathy. The Open Ophthalmology Journal. 2013;7:82–4.
10. Wong RL, Lai TY. Polypoidal choroidal vasculopathy: an update on therapeutic approaches. J Ophthalmic Vis Res. 2013;8:559–71.
11. Koh AH; Expert PCV panel, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686–716.
12. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy with Ranibizumab or alone versus Ranibizumab Monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–64.
13. Chan WM, Lai TY, Liu DT, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.
14. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.
15. Kivok AH, Lai TY, Chan CW, et al. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol. 2010;94:892–7.
16. Byeon SH, Lee SC, Oh HS, et al. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52:57–62.
17. Scassellati-Sforzolini B, Mariotti C, Bryan R, et al. Polypoidal choroidal vasculopathy in Italy. Retina. 2001;21:121–5.
18. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238:752–9.
19. Hatz K, Prunte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98:188–94.
20. Davis SJ, Lauer AK, Flaxel CJ. Polypoidal choroidal vasculopathy in white patients. Retina. 2014;34:2185–91.
21. Kokame GT, Lai JC, Yeung L. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6 month results. Br J Ophthalmol. 2010;94(3):297–301.
22. Hosokawa M, Shiraga F, Yamashita A, et al. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol. 23 Feb 2015 (epub ahead of print).
23. Kokame GT, Yeung L, Teramoto K, et al. Polypoidal choroidal vasculopathy exudation and hemorrhage – results of ranibizumab therapy at one year. Ophthalmologica. 2014;231(2):94–102.
24. Cho HJ, Baek JS, Lee DW, et al. Short-term effectiveness of intravitreal bevacizumab vs ranibizumab injections for patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2012;26(3):157–62.
25. Okhi A, Koijima H, Mandal M, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-Month LAPTOP study results. Am J Ophthalmol. 2013;156(4):644–51.
26. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye(Lond). 2013;27(5):663–4.
27. Chan CK, Jain A, Sadda S, et al. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Retrans Am Ophthalmol Soc. 2014;11:160–98.
28. Yamagishi T, Koizumi H, Yamazaki T, Kinoshita S. Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2014;98(6):780–4.
29. Julien S, Biesemeier A, Taubitz A, et al. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissue of monkey eyes. Br J Ophthalmol. 2014;98(6):813–25.